Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Cytokinetics (CYTK – Research Report) and keeping the price target at ...

Cytokinetics (CYTK) provided guidance for corporate milestones expected to occur in 2025. Expected 2025 Milestones: Cardiac Muscle Programs: ...

Cytokinetics (NASDAQ:CYTK) said EU regulators have validated the market application for its drug aficamten for the treatment of obstructive hypertrophic cardiomyopathy.

The company's lead candidate, aficamten, has been advancing steadily through the regulatory process. Cytokinetics is on track to complete its New Drug Application (NDA) submission to the U.S. Food ...

Cytokinetics, Inc. announced that Sanofi will acquire exclusive rights to aficamten from Corxel Pharmaceuticals for the treatment of hypertrophic cardiomyopathy (HCM) in Greater China. Aficamten ...

Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a ...

Cytokinetics is on track to submit a New Drug Application (NDA) for aficamten in obstructive HCM (oHCM) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2024. This timeline ...

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize ...

The company's lead candidate, aficamten, has been advancing steadily through the regulatory process. Cytokinetics is on track to complete its New Drug Application (NDA) submission to the U.S. Food and ...

(MENAFN- GlobeNewsWire - Nasdaq) SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights ...